Charoensiriwatana Wiyada, Janejai Noppavan, Boonwanich Wanpen, Krasao Piamnukul, Chaisomchit Sumonta, Waiyasilp Supaphan
National Institute of Health, Ministry of Public Health, Nonthaburi, Thailand.
Southeast Asian J Trop Med Public Health. 2003;34 Suppl 3:94-100.
The Neonatal Screening Program for congenital hypothyroidism (CHT) and phenylketonuria (PKU) commenced in 1996 with the objective of bringing better quality of life to people throughout the country, especially in the remote areas. This involved the implementation of routine services to the public health infrastructure all over the country. The plan of action has been designed so that by the year 2000 all public health service units throughout the country may provide screening services which can cover 1.2 million babies/ annum. Implementation of the screening program has been performed through public health sectors all over the country. These involved: education of the health personnel and communities, implementation of routine specimens collection and delivery systems to the central laboratories, establishment of central laboratory screening services, routine follow up and case management. Local in-house reagents using ELISA and IRMA techniques have been developed and utilized as screening and confirmation tests for CHT. In addition, Guthrie's test has been used for PKU screening and the automated Fluorometry has been selected for PKU confirmation. All 724 community hospitals have provided newborn screening services as one of the basic requirements for newborns according to public health policy. Of 1,425,025 babies screened, 3,450 (0.24%) were above the first screening cut off for CHT (TSH > 25 mU/l) and 321 (0.02%) for PKU (PKU > 4mg/dl). With a 63.10% follow up rate, the incidences were 1:3,314 for CHT and 1:237,504 for PKU. Newborn screening has been implemented as routine practice for all public health sectors of the country for CHT and PKU. It is expected that by the year 2003, all Thai newborns will be provided with screening services resulting in a better quality of life for the next generation.
先天性甲状腺功能减退症(CHT)和苯丙酮尿症(PKU)新生儿筛查项目始于1996年,目的是提高全国人民,尤其是偏远地区人民的生活质量。这包括在全国公共卫生基础设施中实施常规服务。行动计划的制定旨在到2000年,全国所有公共卫生服务单位都能提供筛查服务,每年可覆盖120万婴儿。筛查项目通过全国公共卫生部门实施。这些工作包括:对卫生人员和社区进行教育,实施向中心实验室收集和运送常规样本的系统,建立中心实验室筛查服务,进行常规随访和病例管理。已经开发并使用了采用酶联免疫吸附测定法(ELISA)和免疫放射分析(IRMA)技术的本地内部试剂,作为CHT的筛查和确认试验。此外,Guthrie试验已用于PKU筛查,自动荧光测定法已被选用于PKU确认。根据公共卫生政策,所有724家社区医院都提供了新生儿筛查服务,这是新生儿的基本要求之一。在1425025名接受筛查的婴儿中,3450名(0.24%)CHT首次筛查临界值以上(促甲状腺激素>25 mU/l),321名(0.02%)PKU(苯丙氨酸>4mg/dl)。随访率为63.10%,CHT发病率为1:3314,PKU发病率为1:237504。新生儿筛查已在该国所有公共卫生部门作为CHT和PKU的常规做法实施。预计到2003年,所有泰国新生儿都将获得筛查服务,从而为下一代带来更高的生活质量。